Pharmacology News cover art

Pharmacology News

Pharmacology News

By: Circle Of Insight Productions
Listen for free

Join Dr. Carlos on “Pharmacology Insights,” your source for the latest research and news on pharmacology, medications, and street drugs. Each episode delves into cutting-edge discoveries, practical applications, and the evolving landscape of both legal and illicit substances. Gain a deeper understanding of how drugs work, their impacts on health, and the latest trends in medication and drug use. Tune in for expert analysis and insightful discussions that keep you informed on all things pharmacological.Copyright Circle Of Insight Productions Economics Hygiene & Healthy Living Physical Illness & Disease Science Social Sciences
Episodes
  • Escitalopram for Kids’ Anxiety: FDA Approval or Risky Gamble? Weighing the Evidence”

    Escitalopram for Kids’ Anxiety: FDA Approval or Risky Gamble? Weighing the Evidence”
    Jun 8 2026
    In 2023, the FDA approved escitalopram (Lexapro) for generalized anxiety disorder (GAD) in children aged 7 and older, based largely on one industry-sponsored trial showing a small statistical edge over placebo on the Pediatric Anxiety Rating Scale (PARS). Critics argue the benefits fall below clinically meaningful thresholds while risks—particularly a roughly six-fold increase in treatment-emergent suicidal ideation—raise serious concerns about the risk-benefit balance. This episode explores the trial data, study limitations, broader context of pediatric antidepressant use, and what it means for families and clinicians navigating anxiety treatment options.
    Show More Show Less
    8 mins
  • Noribogaine (DMX-1001): A Neuroplastogen Breakthrough for Alcohol Use Disorder or Another Psychedelic Promise with Risks?

    Noribogaine (DMX-1001): A Neuroplastogen Breakthrough for Alcohol Use Disorder or Another Psychedelic Promise with Risks?
    Jun 1 2026
    The FDA accepted DemeRx’s IND for oral noribogaine (DMX-1001) in April 2026, advancing a longer-acting metabolite of ibogaine as a potential treatment for alcohol use disorder (AUD) through neuroplasticity and polypharmacology. We explore the science, preclinical data, early Phase 1 results, related ibogaine/noribogaine studies, and what this could mean for the millions struggling with AUD. Tune in for a balanced look at the pros, cons, limitations, and practical implications of this emerging therapy.20
    Show More Show Less
    5 mins
  • Rising Costs in Healthcare: The 2026 Pharmaceutical Price Increases and Their Implications

    Rising Costs in Healthcare: The 2026 Pharmaceutical Price Increases and Their Implications
    May 27 2026
    I n early 2026, pharmaceutical manufacturers announced list price increases on at least 350 brand-name medications, continuing a pattern that affects treatments for cancer, COVID-19, migraines, and other conditions despite policy efforts to enhance affordability. This episode examines the scope of these hikes, notable examples such as Pfizer’s adjustments to Ibrance and Comirnaty, and the broader context of Medicare negotiations that provide relief for select drugs. Listeners will gain insights into the economic drivers, patient impacts, and potential long-term consequences for healthcare access and innovation.100
    Show More Show Less
    5 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet